WO2006021954A3 - Peptide inhibitors for mediating stress responses - Google Patents

Peptide inhibitors for mediating stress responses Download PDF

Info

Publication number
WO2006021954A3
WO2006021954A3 PCT/IL2005/000908 IL2005000908W WO2006021954A3 WO 2006021954 A3 WO2006021954 A3 WO 2006021954A3 IL 2005000908 W IL2005000908 W IL 2005000908W WO 2006021954 A3 WO2006021954 A3 WO 2006021954A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptides
stress responses
peptide inhibitors
mediating stress
mediating
Prior art date
Application number
PCT/IL2005/000908
Other languages
French (fr)
Other versions
WO2006021954A2 (en
Inventor
Johannes Herkel
Irun R Cohen
Varda Rotter
Ansgar W Lohse
Neta Erez
Avishai Mimran
Na Aman Kam
Original Assignee
Yeda Res & Dev
Johannes Herkel
Irun R Cohen
Varda Rotter
Ansgar W Lohse
Neta Erez
Avishai Mimran
Na Aman Kam
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DK05774723T priority Critical patent/DK1781315T3/en
Priority to EP05774723.0A priority patent/EP1781315B1/en
Priority to US11/573,707 priority patent/US8067008B2/en
Priority to AU2005276117A priority patent/AU2005276117C1/en
Priority to CA2577196A priority patent/CA2577196C/en
Priority to JP2007529133A priority patent/JP4991544B2/en
Priority to PL05774723T priority patent/PL1781315T3/en
Priority to ES05774723.0T priority patent/ES2533697T3/en
Application filed by Yeda Res & Dev, Johannes Herkel, Irun R Cohen, Varda Rotter, Ansgar W Lohse, Neta Erez, Avishai Mimran, Na Aman Kam filed Critical Yeda Res & Dev
Publication of WO2006021954A2 publication Critical patent/WO2006021954A2/en
Publication of WO2006021954A3 publication Critical patent/WO2006021954A3/en
Priority to IL181471A priority patent/IL181471A/en
Priority to US13/287,098 priority patent/US8790653B2/en
Priority to US14/341,814 priority patent/US20140329758A1/en
Priority to US14/754,835 priority patent/US20150297693A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

The present invention relates to peptides capable of inhibiting cellular and immune stress responses in a eukaryotic cell. The invention provides compositions and methods for the treatment of human degenerative diseases and inflammation, utilizing peptides recognized by monoclonal anti-DNA antibodies, the peptides having anti-apoptotic and anti-inflammatory activity. The invention further provides antibody molecules and uses thereof for the isolation of such peptides.
PCT/IL2005/000908 2004-08-23 2005-08-23 Peptide inhibitors for mediating stress responses WO2006021954A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
PL05774723T PL1781315T3 (en) 2004-08-23 2005-08-23 Peptide inhibitors for mediating stress responses
US11/573,707 US8067008B2 (en) 2004-08-23 2005-08-23 Peptide inhibitors for mediating stress responses
AU2005276117A AU2005276117C1 (en) 2004-08-23 2005-08-23 Peptide inhibitors for mediating stress responses
CA2577196A CA2577196C (en) 2004-08-23 2005-08-23 Peptide inhibitors for mediating stress responses
JP2007529133A JP4991544B2 (en) 2004-08-23 2005-08-23 Peptide inhibitors for mediating stress responses
DK05774723T DK1781315T3 (en) 2004-08-23 2005-08-23 PEPTIDE INHIBITORS FOR MEDIATION OF stress responses
ES05774723.0T ES2533697T3 (en) 2004-08-23 2005-08-23 Peptide inhibitors to mediate stress responses
EP05774723.0A EP1781315B1 (en) 2004-08-23 2005-08-23 Peptide inhibitors for mediating stress responses
IL181471A IL181471A (en) 2004-08-23 2007-02-20 Peptides, pharmaceutical compositions comprising same and uses thereof in the manufacture of a medicament for treating conditions associated with stress responses
US13/287,098 US8790653B2 (en) 2004-08-23 2011-11-01 Peptide inhibitors for mediating stress responses
US14/341,814 US20140329758A1 (en) 2004-08-23 2014-07-27 Peptide inhibitors for mediating stress responses
US14/754,835 US20150297693A1 (en) 2004-08-23 2015-06-30 Peptide inhibitors for mediating stress responses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60325504P 2004-08-23 2004-08-23
US60/603,255 2004-08-23

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/573,707 A-371-Of-International US8067008B2 (en) 2004-08-23 2005-08-23 Peptide inhibitors for mediating stress responses
US13/287,098 Division US8790653B2 (en) 2004-08-23 2011-11-01 Peptide inhibitors for mediating stress responses

Publications (2)

Publication Number Publication Date
WO2006021954A2 WO2006021954A2 (en) 2006-03-02
WO2006021954A3 true WO2006021954A3 (en) 2007-02-08

Family

ID=35967919

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2005/000908 WO2006021954A2 (en) 2004-08-23 2005-08-23 Peptide inhibitors for mediating stress responses

Country Status (11)

Country Link
US (4) US8067008B2 (en)
EP (2) EP1781315B1 (en)
JP (1) JP4991544B2 (en)
CN (2) CN101035554A (en)
AU (1) AU2005276117C1 (en)
CA (1) CA2577196C (en)
DK (1) DK1781315T3 (en)
ES (1) ES2533697T3 (en)
HU (1) HUE024953T2 (en)
PL (1) PL1781315T3 (en)
WO (1) WO2006021954A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2804764C2 (en) * 2018-05-31 2023-10-05 Иммунити Фарма Лтд. Compositions and methods of their use for the treatment of amyotrophic lateral sclerosis (als)
US11852634B2 (en) 2011-05-23 2023-12-26 Yeda Research And Development Co. Ltd. Use of AKT phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006021954A2 (en) 2004-08-23 2006-03-02 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Peptide inhibitors for mediating stress responses
JP7242059B2 (en) * 2017-01-05 2023-03-20 イエダ リサーチ アンド ディベロプメント カンパニー リミテッド Peptides for the treatment of Sjögren's syndrome
WO2019229757A1 (en) * 2018-05-31 2019-12-05 Immunity Pharma Ltd. Compositions and methods of using same for treating amyotrophic lateral sclerosis (als)
JP7395517B2 (en) * 2018-07-11 2023-12-11 イミュニティ ファルマ リミテッド Peptide compounds and their therapeutic uses
IL272074A (en) 2020-01-15 2021-07-29 Immunity Pharma Ltd Peptide compounds and methods of treating diseases using same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023082A1 (en) * 1998-10-19 2000-04-27 Yeda Research And Development Co. Ltd. Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens
EP1408114A1 (en) * 2002-10-11 2004-04-14 BioVisioN AG Modular antigen-transporter-molecules (MAT-molecules) for modulating immune responses, corresponding constructs and methods and uses thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US5733731A (en) 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
US5270170A (en) * 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
DE69309472T2 (en) 1992-01-23 1997-10-23 Merck Patent Gmbh FUSION PROTEINS OF MONOMERS AND DIMERS OF ANTIBODY FRAGMENTS
GB9224784D0 (en) 1992-11-26 1993-01-13 Univ Dundee Cellular protein
US5922545A (en) 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
WO1996013583A2 (en) 1994-10-20 1996-05-09 Morphosys Gesellschaft Für Proteinoptimierung Mbh Targeted hetero-association of recombinant proteins to multi-functional complexes
JPH11508126A (en) 1995-05-23 1999-07-21 モルフォシス ゲゼルシャフト ファー プロテインオプティマイルング エムベーハー Multimeric protein
AU4474497A (en) 1996-10-08 1998-05-05 U-Bisys B.V. Methods and means for selecting peptides and proteins having specific affinity for a target
EP1019040B1 (en) 1997-05-23 2004-09-29 Bayer Corporation Aryl ureas for the treatment of inflammatory or immunomodulatory diseases
IL121041A0 (en) 1997-06-09 1997-11-20 Yeda Res & Dev Immunogenic compositions for induction of anti-tumor immunity
WO1999016790A1 (en) * 1997-09-26 1999-04-08 University Technologies International, Inc. Use of the tumour suppressor gene p33ing1 for modulation of p53 activity and in tumour diagnosis
JP2001521934A (en) 1997-11-03 2001-11-13 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Aromatic heterocyclic compounds as anti-inflammatory drugs
ATE297383T1 (en) 1997-12-22 2005-06-15 Bayer Pharmaceuticals Corp INHIBITION OF P38 KINASE USING SYMMETRIC AND ASYMMETRIC DIPHENYL UREASES
EP0928968A1 (en) 1998-01-12 1999-07-14 Universität Basel Screening method for apoptosis and necrosis
WO2000044364A2 (en) * 1999-01-29 2000-08-03 The Board Of Trustees Of The University Of Illinois P53 inhibitors and their use for the treatment of cancer, hyperthermia, hypoxia, a burn, trauma to the central nervous system, a seizure, acute inflammation, tissue ageing, preservation of organs for transplant and preparation of a host for bone marrow transplant
JP2003503456A (en) 1999-07-02 2003-01-28 スチュアート エイ． リプトン How to reduce nerve injury or apoptosis
US6630584B1 (en) 2000-03-16 2003-10-07 Ramot At Tel-Aviv University Ltd. Single chain antibody against mutant p53
EP1381839A4 (en) 2001-04-03 2005-10-12 Univ Leland Stanford Junior Method of imaging cell death in vivo
US20050019915A1 (en) 2001-06-21 2005-01-27 Bennett C. Frank Antisense modulation of superoxide dismutase 1, soluble expression
CN101709078B (en) 2002-01-29 2013-04-17 Posco公司 Immune-modulating peptide
US7517857B2 (en) 2002-01-29 2009-04-14 Posco Immune-modulating peptide
ATE534669T1 (en) * 2002-05-28 2011-12-15 Omrix Biopharmaceuticals Inc METHOD FOR OBTAINING ANTI-IDIOTYPE ANTIBODIES
GB0223193D0 (en) * 2002-10-07 2002-11-13 Ludwig Inst Cancer Res Polypeptide
US20060014719A1 (en) 2004-07-13 2006-01-19 Glycogenesys, Inc. Method for treating neurodegenerative diseases
WO2006021954A2 (en) 2004-08-23 2006-03-02 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Peptide inhibitors for mediating stress responses
GB0425625D0 (en) 2004-11-22 2004-12-22 Royal College Of Surgeons Ie Treatment of disease
BRPI0709033A2 (en) 2006-03-29 2011-06-21 Velacor Therapeutics Pty Ltd pharmaceutical composition, methods of treating or preventing neurodegenerative disease in a person, inhibiting or reducing phosphorylation of a tau protein in a neuron, glial cell or lewy body, enhancing pp2a activity and inhibiting gsk3 activity in a neuron or glial cell and use of selenate or pharmaceutically acceptable salt thereof
AU2007297539A1 (en) 2006-09-20 2008-03-27 Medivation Neurology, Inc. Methods and compositions for treating amyotrophic lateral sclerosis (ALS)
ITMI20070127A1 (en) 2007-01-29 2008-07-30 Fond I R C C S E-O PEPTIDES PROTEINS FOR THE PREVENTION AND-OR CARE OF NEURODEGENERATIVE DISEASES
US20100298306A1 (en) 2007-10-22 2010-11-25 Memory Pharmaceuticals Corporation (1,4-Diaza-bicyclo[3.2.2]non-6-en-4-yl)-heterocyclyl-methanone Ligands for Nicotinic Acetylcholine Receptors, Useful for the Treatment of Disease
EP2304436A1 (en) 2008-07-10 2011-04-06 Nodality, Inc. Methods for diagnosis, prognosis and treatment
US20100292281A1 (en) 2009-05-15 2010-11-18 The University Of Kentucky Research Foundation Treatment of mci and alzheimer's disease
EA201290041A1 (en) 2009-08-06 2012-07-30 Ньюралтус Фармасьютикалс, Инк. TREATMENT OF DISORDERS ASSOCIATED WITH MACROPHAGES
EP3263127B1 (en) 2011-05-23 2019-08-21 Yeda Research and Development Co. Ltd Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023082A1 (en) * 1998-10-19 2000-04-27 Yeda Research And Development Co. Ltd. Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens
EP1408114A1 (en) * 2002-10-11 2004-04-14 BioVisioN AG Modular antigen-transporter-molecules (MAT-molecules) for modulating immune responses, corresponding constructs and methods and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE GENESEQ [online] CRAMERI ET AL., XP003005909, accession no. EMBL Database accession no. (ADM57310) *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11852634B2 (en) 2011-05-23 2023-12-26 Yeda Research And Development Co. Ltd. Use of AKT phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
RU2804764C2 (en) * 2018-05-31 2023-10-05 Иммунити Фарма Лтд. Compositions and methods of their use for the treatment of amyotrophic lateral sclerosis (als)

Also Published As

Publication number Publication date
DK1781315T3 (en) 2015-04-20
CA2577196A1 (en) 2006-03-02
EP2578226B1 (en) 2017-10-25
HUE024953T2 (en) 2016-02-29
CA2577196C (en) 2016-01-12
EP1781315B1 (en) 2015-01-07
PL1781315T3 (en) 2015-08-31
CN101035554A (en) 2007-09-12
CN103214555B (en) 2015-05-13
AU2005276117C1 (en) 2013-04-18
US8790653B2 (en) 2014-07-29
JP2008510796A (en) 2008-04-10
JP4991544B2 (en) 2012-08-01
EP2578226A1 (en) 2013-04-10
WO2006021954A2 (en) 2006-03-02
US8067008B2 (en) 2011-11-29
EP1781315A2 (en) 2007-05-09
CN103214555A (en) 2013-07-24
US20140329758A1 (en) 2014-11-06
EP1781315A4 (en) 2009-07-22
US20150297693A1 (en) 2015-10-22
US20120171233A1 (en) 2012-07-05
AU2005276117A1 (en) 2006-03-02
AU2005276117B2 (en) 2012-04-12
ES2533697T3 (en) 2015-04-14
US20080267983A1 (en) 2008-10-30

Similar Documents

Publication Publication Date Title
EA201000424A1 (en) ANTIBODIES TO IL-23
WO2007033230A3 (en) Anti-cd3 antibody formulations
EP2399936A3 (en) Anti-CD154 antibodies
WO2005052000A3 (en) Anti-il-20 antibodies and binding partners and methods of using in inflammation
EP2287195A3 (en) Pan-KIR2DL NK-receptor antibodies and their use in diagnostik and therapy
WO2006021954A3 (en) Peptide inhibitors for mediating stress responses
EP1603949B8 (en) Antibodies against human il-21 receptor and uses therefor
WO2007011363A3 (en) Binding domain fusion proteins
WO2004085475A3 (en) Anti-il-20 antibodies and binding partners and methods of using in inflammation
WO2011002968A3 (en) Polypeptides and method of treatment
WO2010108153A3 (en) Carrier immunoglobulins and uses thereof
AU2013205271B2 (en) Human CGRP receptor binding proteins
WO2006116181A3 (en) Regulatory t cell mediator proteins and uses thereof
WO2007044756A3 (en) Monoclonal antibodies recognizing human ccr8
WO2001098358A3 (en) Compositions for identification and isolation of stem cells
WO2006021955A3 (en) Use of bat monoclonal antibody for immunotherapy
WO2007116360A3 (en) Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
TW200510459A (en) RG1 antibodies and uses thereof
WO2007019865A3 (en) Therapy with cd4 binding peptides and radiation
WO2007010080A3 (en) Novel carbosilane dendrimers, preparation method thereof and use of same
WO2009135861A3 (en) Humanized antibodies against human interferon-alpha
NO330984B1 (en) Amino acid phenoxy esters, processes for the preparation of such, intermediates in the synthetic route, pharmaceutical compositions comprising such and the use thereof for the preparation of pharmaceutical preparations for the treatment of disease
EP2463304A3 (en) Monoclonal antibodies that neutralize anthrax toxins
EA200800601A1 (en) CONNECTING FAS ANTIBODIES
WO2007075915A3 (en) Monoclonal antibodies against orthopoxviruses

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005774723

Country of ref document: EP

Ref document number: 2005276117

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2577196

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 181471

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2007529133

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 200580028458.7

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 1729/DELNP/2007

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2005276117

Country of ref document: AU

Date of ref document: 20050823

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005276117

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005774723

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11573707

Country of ref document: US